| The consensus coding sequences of human breast and colorectal cancers T Sjoblom, S Jones, LD Wood, DW Parsons, J Lin, TD Barber, ... science 314 (5797), 268-274, 2006 | 4243 | 2006 |
| The genomic landscapes of human breast and colorectal cancers LD Wood, DW Parsons, S Jones, J Lin, T Sjoblom, RJ Leary, D Shen, ... Science 318 (5853), 1108-1113, 2007 | 3751 | 2007 |
| DNMT1 and DNMT3b cooperate to silence genes in human cancer cells I Rhee, KE Bachman, BH Park, KW Jair, RWC Yen, KE Schuebel, H Cui, ... Nature 416 (6880), 552-556, 2002 | 1559 | 2002 |
| AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discovery, 2017 | 1234 | 2017 |
| Role of BAX in the apoptotic response to anticancer agents L Zhang, J Yu, BH Park, KW Kinzler, B Vogelstein Science 290 (5493), 989-992, 2000 | 1108 | 2000 |
| The PIK3CA gene is mutated with high frequency in human breast cancers KE Bachman, P Argani, Y Samuels, N Silliman, J Ptak, S Szabo, ... Cancer biology & therapy 3 (8), 772-775, 2004 | 880 | 2004 |
| Mutation of the PIK3CA oncogene in human cancers B Karakas, KE Bachman, BH Park British journal of cancer 94 (4), 455-459, 2006 | 630 | 2006 |
| A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. G Torre-Amione, RD Beauchamp, H Koeppen, BH Park, H Schreiber, ... Proceedings of the National Academy of Sciences 87 (4), 1486-1490, 1990 | 570 | 1990 |
| P21 and p27: roles in carcinogenesis and drug resistance AM Abukhdeir, BH Park Expert reviews in molecular medicine 10, e19, 2008 | 542 | 2008 |
| Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene KE Bachman, BH Park, I Rhee, H Rajagopalan, JG Herman, SB Baylin, ... Cancer cell 3 (1), 89-95, 2003 | 536 | 2003 |
| NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming AJ Kuo, P Cheung, K Chen, BM Zee, M Kioi, J Lauring, Y Xi, BH Park, ... Molecular cell 44 (4), 609-620, 2011 | 450 | 2011 |
| Detection of cancer DNA in plasma of patients with early-stage breast cancer JA Beaver, D Jelovac, S Balukrishna, RL Cochran, S Croessmann, ... Clinical cancer research 20 (10), 2643-2650, 2014 | 430 | 2014 |
| PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients TL Lotan, B Gurel, S Sutcliffe, D Esopi, W Liu, J Xu, JL Hicks, BH Park, ... Clinical cancer research 17 (20), 6563-6573, 2011 | 384 | 2011 |
| Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers RJ Leary, JC Lin, J Cummins, S Boca, LD Wood, DW Parsons, S Jones, ... Proceedings of the National Academy of Sciences 105 (42), 16224-16229, 2008 | 384 | 2008 |
| Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood MJ Higgins, D Jelovac, E Barnathan, B Blair, S Slater, P Powers, J Zorzi, ... Clinical cancer research 18 (12), 3462-3469, 2012 | 366 | 2012 |
| Male breast cancer: a disease distinct from female breast cancer A Gucalp, TA Traina, JR Eisner, JS Parker, SR Selitsky, BH Park, AD Elias, ... Breast cancer research and treatment 173, 37-48, 2019 | 341 | 2019 |
| Genetic disruption of PPARδ decreases the tumorigenicity of human colon cancer cells BH Park, B Vogelstein, KW Kinzler Proceedings of the National Academy of Sciences 98 (5), 2598-2603, 2001 | 339 | 2001 |
| Duel nature of TGF-β signaling: tumor suppressor vs. tumor promoter KE Bachman, BH Park Current opinion in oncology 17 (1), 49-54, 2005 | 254 | 2005 |
| GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas A Cimino-Mathews, AP Subhawong, PB Illei, R Sharma, MK Halushka, ... Human pathology 44 (7), 1341-1349, 2013 | 226 | 2013 |
| The multiple myeloma–associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity J Lauring, AM Abukhdeir, H Konishi, JP Garay, JP Gustin, Q Wang, ... Blood, The Journal of the American Society of Hematology 111 (2), 856-864, 2008 | 210 | 2008 |
Pedram ArganiProfessor of Pathology and Oncology, Johns Hopkins UniversityVerified email at jhmi.edu
